OTCPK:MMDZ.F

Stock Analysis Report

Mainstay Medical International

Executive Summary

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Mainstay Medical International's last earnings update was 191 days ago.
  • Mainstay Medical International is not covered by any analysts.

Share Price & News

How has Mainstay Medical International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

MMDZ.F

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

MMDZ.F

9.7%

US Medical Equipment

0.7%

US Market

No trading data on MMDZ.F.

No trading data on MMDZ.F.


Share holder returns

MMDZ.FIndustryMarket
7 Day0%1.2%-0.6%
30 Day0%3.5%4.9%
90 Day0%3.2%1.7%
1 Yearn/a10.6%9.7%3.0%0.7%
3 Yearn/a70.6%65.4%44.8%35.4%
5 Yearn/a139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is Mainstay Medical International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mainstay Medical International undervalued based on future cash flows and its price relative to the stock market?

2.24x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Mainstay Medical International to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Mainstay Medical International to establish if it is available at substantial discount.


Price Based on Earnings

Mainstay Medical International is loss making, we can't compare its value to the US Medical Equipment industry average.

Mainstay Medical International is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Mainstay Medical International, we can't assess if its growth is good value.


Price Based on Value of Assets

Mainstay Medical International is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Mainstay Medical International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mainstay Medical International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MMDZ.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Mainstay Medical International's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Mainstay Medical International performed over the past 5 years?

20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Mainstay Medical International does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Mainstay Medical International's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Mainstay Medical International's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Mainstay Medical International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Mainstay Medical International has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Mainstay Medical International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Mainstay Medical International's financial position?


Financial Position Analysis

Mainstay Medical International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Mainstay Medical International's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Mainstay Medical International's level of debt (84.4%) compared to net worth is high (greater than 40%).

Mainstay Medical International had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.5x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Mainstay Medical International has less than a year of cash runway based on current free cash flow.

Mainstay Medical International has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.1% each year.


Next Steps

Dividend

What is Mainstay Medical International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Mainstay Medical International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Mainstay Medical International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Mainstay Medical International has not reported any payouts.

Unable to verify if Mainstay Medical International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Mainstay Medical International has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Mainstay Medical International's salary, the management and board of directors tenure and is there insider trading?

0.9yrs

Average management tenure


CEO

Jason Hannon (46yo)

1.4yrs

Tenure

US$722,675

Compensation

Mr. Jason Marshall Hannon, Esq., serves as Director of Kuros Biosciences AG since June 14, 2018. He has been the Chief Executive Officer of Mainstay Medical International plc since October 9, 2017. Mr. Han ...


CEO Compensation Analysis

Jason's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Jason to compare compensation growth.


Management Age and Tenure

0.9yrs

Average Tenure

46.5yo

Average Age

The average tenure for the Mainstay Medical International management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.7yrs

Average Tenure

52.5yo

Average Age

The tenure for the Mainstay Medical International board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Jason Hannon (46yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$722.68k
  • Matt Onaitis (47yo)

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Jan Heemels (55yo)

    Vice President of Marketing

    • Tenure: 1.2yrs
  • Prashant Rawat (44yo)

    Chief Operating Officer

    • Tenure: 0yrs
  • Wolfgang Frisch

    VP & MD of Germany

    • Tenure: 0.7yrs

Board Members

  • Antoine Papiernik-Berkhauer (52yo)

    Non-Executive Director

    • Tenure: 4.8yrs
  • Greg Garfield (55yo)

    Non-Executive Director

    • Tenure: 2.7yrs
  • Oern Stuge (64yo)

    Independent Non-Executive Chairman

    • Tenure: 0yrs
    • Compensation: US$105.52k
  • Jason Hannon (46yo)

    CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$722.68k
  • David Brabazon (48yo)

    Independent Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: US$59.09k
  • James Reinstein (53yo)

    Independent Non-Executive Director

    • Tenure: 3.7yrs
    • Compensation: US$59.09k
  • Dan Sachs (53yo)

    Non-Executive Director

    • Tenure: 4.8yrs
  • Nael Kassar (39yo)

    Non-Executive Director

    • Tenure: 2.7yrs

Company Information

Mainstay Medical International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mainstay Medical International plc
  • Ticker: MMDZ.F
  • Exchange: OTCPK
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €31.227m
  • Listing Market Cap: €35.048m
  • Shares outstanding: 8.77m
  • Website: https://www.mainstay-medical.com/en

Number of Employees


Location

  • Mainstay Medical International plc
  • 77 Sir John Rogerson’s Quay
  • Block C
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MSTY1ISE (Irish Stock Exchange)YesNew Ordinary SharesIEEURApr 2014
MSTYENXTPA (Euronext Paris)YesNew Ordinary SharesFREURApr 2014
MSTYPBATS-CHIXE (BATS 'Chi-X Europe')YesNew Ordinary SharesGBEURApr 2014
0QUDLSE (London Stock Exchange)YesNew Ordinary SharesGBEURApr 2014
MMDZ.FOTCPK (Pink Sheets LLC)YesNew Ordinary SharesUSUSDApr 2014

Biography

Mainstay Medical International plc, together with its subsidiaries, operates as a medical device company in Europe, the United States, and Australia. The company develops ReActiv8, an implantable restorati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/03/31 00:59
End of Day Share Price2018/12/31 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.